VTGN [NASD]
VistaGen Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.31 Insider Own0.30% Shs Outstand206.81M Perf Week40.85%
Market Cap55.80M Forward P/E- EPS next Y-0.28 Insider Trans197.13% Shs Float205.00M Perf Month119.62%
Income-64.70M PEG- EPS next Q-0.07 Inst Own28.90% Short Float / Ratio6.05% / 1.89 Perf Quarter149.34%
Sales-0.19M P/S- EPS this Y49.90% Inst Trans-60.56% Short Interest12.40M Perf Half Y108.13%
Book/sh0.14 P/B2.14 EPS next Y12.90% ROA-97.80% Target Price- Perf Year-77.45%
Cash/sh0.19 P/C1.58 EPS next 5Y- ROE-117.40% 52W Range0.08 - 1.79 Perf YTD213.01%
Dividend- P/FCF- EPS past 5Y30.70% ROI-73.90% 52W High-81.99% Beta0.91
Dividend %- Quick Ratio6.10 Sales past 5Y-2.40% Gross Margin- 52W Low319.79% ATR0.03
Employees34 Current Ratio6.10 Sales Q/Q- Oper. Margin- RSI (14)81.74 Volatility18.80% 15.29%
OptionableYes Debt/Eq0.02 EPS Q/Q-24.00% Profit Margin- Rel Volume3.18 Prev Close0.30
ShortableYes LT Debt/Eq0.00 EarningsNov 10 AMC Payout- Avg Volume6.56M Price0.32
Recom2.30 SMA2066.08% SMA50115.07% SMA200-28.14% Volume2,466,001 Change7.47%
Jul-22-22Downgrade William Blair Outperform → Mkt Perform
Jul-22-22Downgrade Robert W. Baird Outperform → Neutral
Jul-22-22Downgrade Jefferies Buy → Hold
May-20-21Initiated Robert W. Baird Outperform $9
Feb-18-21Initiated Jefferies Buy $6
Jan-04-21Upgrade William Blair Mkt Perform → Outperform
Jun-27-18Initiated Maxim Group Buy $6
Feb-08-18Reiterated Chardan Capital Markets Buy $30 → $22
Mar-28-17Initiated Maxim Group Buy $4
Feb-06-23 09:09AM
Feb-02-23 09:00AM
Jan-24-23 08:30AM
Jan-19-23 08:30AM
Jan-10-23 08:30AM
08:30AM Loading…
Dec-30-22 08:30AM
Dec-21-22 10:56AM
08:30AM
Dec-16-22 08:35AM
Dec-13-22 08:35AM
Dec-06-22 08:30AM
Nov-30-22 08:30AM
Nov-17-22 08:30AM
Nov-15-22 12:00PM
Nov-10-22 06:45PM
04:30PM Loading…
04:30PM
Nov-04-22 08:30AM
Nov-03-22 08:30AM
Oct-26-22 09:00AM
Oct-22-22 08:02AM
Oct-19-22 04:30PM
Oct-06-22 08:30AM
Oct-03-22 08:30AM
Sep-24-22 08:10AM
Sep-20-22 08:30AM
Sep-19-22 08:30AM
Sep-09-22 08:30AM
Sep-08-22 02:24PM
08:00AM
Aug-11-22 04:20PM
08:30AM Loading…
Aug-09-22 08:30AM
Jul-22-22 09:06AM
08:00AM
Jul-20-22 10:42AM
Jul-12-22 08:30AM
Jul-07-22 08:30AM
Jun-23-22 05:35PM
04:20PM
Jun-22-22 08:30AM
Jun-17-22 08:30AM
Jun-02-22 08:30AM
May-31-22 05:20AM
May-27-22 08:30AM
May-19-22 06:00PM
May-10-22 10:34AM
May-05-22 08:30AM
May-02-22 08:00AM
Apr-21-22 08:00AM
Apr-12-22 02:57PM
11:20AM
07:00AM
Apr-07-22 12:05PM
Apr-05-22 12:08PM
Mar-24-22 08:00AM
Mar-19-22 08:38AM
Feb-10-22 05:55PM
04:20PM
Feb-07-22 08:00AM
Feb-03-22 03:01PM
Nov-19-21 11:17AM
Nov-16-21 08:30AM
Nov-14-21 08:53AM
Nov-11-21 04:31AM
Nov-10-21 07:05PM
04:20PM
Nov-04-21 03:01PM
08:00AM
Oct-14-21 12:18PM
08:00AM
Oct-05-21 12:06PM
08:00AM
Sep-20-21 02:38PM
Sep-13-21 06:00AM
Sep-08-21 08:00AM
Aug-13-21 06:31AM
Aug-12-21 08:05PM
04:25PM
Aug-09-21 04:05PM
Aug-02-21 09:05AM
08:00AM
Jul-22-21 08:00AM
Jul-21-21 08:28AM
Jul-09-21 08:30AM
06:54AM
Jul-07-21 08:30AM
Jun-30-21 04:14PM
Jun-29-21 04:15PM
Jun-25-21 08:00AM
Jun-16-21 08:00AM
May-26-21 08:00AM
May-20-21 08:00AM
May-19-21 08:37AM
May-04-21 08:00AM
Apr-27-21 09:33AM
08:00AM
Mar-31-21 10:30PM
Mar-22-21 08:30AM
Mar-16-21 07:46AM
Mar-11-21 08:30AM
08:17AM
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GIN JERRY BDirectorAug 18Buy0.18100,00017,870100,000Aug 22 05:12 PM
GIN JERRY BDirectorAug 18Buy0.18100,00017,870100,000Aug 22 05:12 PM
Singh ShawnCHIEF EXECUTIVE OFFICERAug 17Buy0.17600,000103,200626,234Aug 18 03:56 PM
Adler Reid G.CHIEF LEGAL OFFICERAug 17Buy0.17300,00050,910334,629Aug 19 03:45 PM
Venrock Healthcare Capital Par10% OwnerJul 12Sale0.8960,00053,40020,637,286Jul 14 05:33 PM
Singh ShawnCHIEF EXECUTIVE OFFICERMay 12Option Exercise1.00100,000100,000148,998May 16 01:39 PM